Meeting
2022 ASCO Annual Meeting
Management of checkpoint inhibitor toxicity and survival in patients with advanced melanoma.
Authors
Olivier Jules van Not
University Medical Center Utrecht, Leiden, Netherlands
Olivier Jules van Not , Rik Jasper Verheijden , Alfonsus Johannes Maria van den Eertwegh , John B. A. G. Haanen , Christian U. Blank , Maureen J.B. Aarts , Franchette Van Den Berkmortel , Jan Willem de Groot , Geke Hospers , Ellen Kapiteijn , Melissa Melanie de Meza , Djura Piersma , Rozemarijn Van Rijn , Marion Stevense - den Boer , Astrid Aplonia Maria Van Der Veldt , Gerard Vreugdenhil , Marye J. Boers-Sonderen , Willeke Blokx , Michel W.J.M. Wouters , Karijn Suijkerbuijk
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9546)
DOI
10.1200/JCO.2022.40.16_suppl.9546
Abstract #
9546
Poster Bd #
139
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Estimating treatment-free survival (TFS) over extended follow-up in patients (pts) with advanced melanoma (MEL) treated with immune-checkpoint inhibitors (ICIs): Five-year follow-up of CheckMate 067.
First Author: Meredith M. Regan
Poster
2019 ASCO Annual Meeting
Sensitivity of treatment-free survival (TFS), a novel outcome, to subgroup analyses of patients (pts) with advanced melanoma (MEL) treated with immune checkpoint inhibitors (ICI).
First Author: Charlene Mantia
Poster
2023 ASCO Quality Care Symposium
Learning about and living with toxicity: A qualitative study of patients receiving immune checkpoint inhibitors for melanoma or lung cancer and their caregivers.
First Author: Ayo Samuel Falade
Poster
2023 ASCO Annual Meeting
Association between physical activity, immune-related adverse events, and mortality in patients undergoing immune checkpoint inhibition.
First Author: Rik Jasper Verheijden